Miguel Ángel Hernández-Rodríguez1, Ermengol Sempere-Verdú2, Caterina Vicens-Caldentey3, Francisca González-Rubio4, Félix Miguel-García5, Vicente Palop-Larrea6, Ramón Orueta-Sánchez7, Óscar Esteban-Jiménez8, Mara Sempere-Manuel9, María Pilar Arroyo-Aniés10, Buenaventura Fernández-San José11. 1. Dirección del Servicio Canario de la Salud, Plan de Salud de Canarias. Santa Cruz de Tenerife, Spain. 2. Centro de Salud de Paterna, Valencia, Conselleria de Sanitat Universal i Salut Pública. Generalitat Valenciana, Spain. 3. Centro de Salud Son Serra-La Vileta. Institut d'Investigació Sanitaria Illes Balears (IDISBA), Servicio de Salud de las Islas Baleares Ib-salut. Palma, Islas Baleares, Spain. 4. Centro de Salud Delicias Sur, Zaragoza. Servicio Aragonés de Salud, Aragón, Spain. 5. Ministerio de Sanidad, Consumo y Bienestar Social, Madrid, Spain. 6. Hospital de Denia. Marina Salud. Alicante, Conselleria de Sanitat Universal i Salut Pública, Spain. 7. Centro de Salud de Sillería. Toledo Servicio de Salud de Castilla-La Mancha, Spain. 8. Centro de Salud Borja, Zaragoza, Servicio Aragonés de Salud, Aragón, Spain. 9. Centro de Salud de Sueca. Valencia. Conselleria de Sanitat Universal i Salut Pública. Generalitat Valenciana. Comunitat Valenciana, Spain. 10. Centro de Salud Huarte, Pamplona, Servicio Navarro de Salud, Spain. 11. Centro de Salud de Canalejas. Las Palmas de Gran Canaria. Servicio Canario de la Salud, Spain.
Abstract
PURPOSE: To analyze the evolution of the prevalence of polypharmacy and excessive polypharmacy in a Spanish population, and to improve the identification of patients with polypharmacy. METHODS: A descriptive, annual cross-sectional observational study was carried out. PATIENTS: individuals over 14 years of age included in a multiregional primary care database of the Spanish population (BIFAP). ANALYSIS: prescription data. Period 2005-2015. VARIABLES: proportion of patients with polypharmacy (simultaneous prescription of ≥5 drugs) and excessive polypharmacy (≥10 drugs) for at least 6 months, according to sex and age groups. A trend analysis of the studied period was performed (overall, and by sex and age groups). RESULTS: The data are reported on a comparative basis (2005 vs 2015). Number of patients analyzed: 2664743 vs 4 002 877. The prevalence of polypharmacy increased significantly (2.5% vs 8.9%, P-value for trend <0.001), being greater in females throughout the study period and in the group aged ≥80 years (P-value for trends <0.001). The prevalence of excessive polypharmacy also increased significantly (0.1% vs 1%, P-value for trend <0.001), being higher in the group aged ≥80 years (P-value for trend <0.001). The proportion of patients with no chronic treatment decreased (80.2% vs 63.1%). CONCLUSIONS: The prevalence of polypharmacy in this Spanish population has tripled in the period 2005-2015, while excessive polypharmacy has increased 10-fold. These increments are seen in both sexes and in all age groups, particularly in individuals over 80 years of age. The proportion of patients without chronic treatments has decreased.
PURPOSE: To analyze the evolution of the prevalence of polypharmacy and excessive polypharmacy in a Spanish population, and to improve the identification of patients with polypharmacy. METHODS: A descriptive, annual cross-sectional observational study was carried out. PATIENTS: individuals over 14 years of age included in a multiregional primary care database of the Spanish population (BIFAP). ANALYSIS: prescription data. Period 2005-2015. VARIABLES: proportion of patients with polypharmacy (simultaneous prescription of ≥5 drugs) and excessive polypharmacy (≥10 drugs) for at least 6 months, according to sex and age groups. A trend analysis of the studied period was performed (overall, and by sex and age groups). RESULTS: The data are reported on a comparative basis (2005 vs 2015). Number of patients analyzed: 2664743 vs 4 002 877. The prevalence of polypharmacy increased significantly (2.5% vs 8.9%, P-value for trend <0.001), being greater in females throughout the study period and in the group aged ≥80 years (P-value for trends <0.001). The prevalence of excessive polypharmacy also increased significantly (0.1% vs 1%, P-value for trend <0.001), being higher in the group aged ≥80 years (P-value for trend <0.001). The proportion of patients with no chronic treatment decreased (80.2% vs 63.1%). CONCLUSIONS: The prevalence of polypharmacy in this Spanish population has tripled in the period 2005-2015, while excessive polypharmacy has increased 10-fold. These increments are seen in both sexes and in all age groups, particularly in individuals over 80 years of age. The proportion of patients without chronic treatments has decreased.
Authors: Miguel Ángel Hernández-Rodríguez; Ermengol Sempere-Verdú; Caterina Vicens-Caldentey; Francisca González-Rubio; Félix Miguel-García; Vicente Palop-Larrea; Ramón Orueta-Sánchez; Óscar Esteban-Jiménez; Mara Sempere-Manuel; María Pilar Arroyo-Aniés; Buenaventura Fernández-San José; José Ignacio de Juan-Roldán; Ignatios Ioakeim-Skoufa Journal: Int J Environ Res Public Health Date: 2021-04-29 Impact factor: 3.390
Authors: Jose Ignacio de Juan-Roldán; Marcos Castillo-Jimena; Alba González-Hevilla; Clara Sánchez-Sánchez; Antonio J García-Ruiz; Enrique Gavilán-Moral Journal: BMJ Open Date: 2022-04-21 Impact factor: 3.006
Authors: Alexander Ferro-Uriguen; Idoia Beobide-Telleria; Javier Gil-Goikouria; Petra Teresa Peña-Labour; Andrea Díaz-Vila; Arlovia Teresa Herasme-Grullón; Enrique Echevarría-Orella; Jesús Seco-Calvo Journal: Front Public Health Date: 2022-10-03
Authors: Núria Molist-Brunet; Daniel Sevilla-Sánchez; Emma Puigoriol-Juvanteny; Lorena Bajo-Peñas; Immaculada Cantizano-Baldo; Laia Cabanas-Collell; Joan Espaulella-Panicot Journal: Int J Environ Res Public Health Date: 2022-03-14 Impact factor: 3.390